Lubrizol Sells Active Pharmaceutical Ingredient and Intermediate Compounds Business
This is Lubrizol's fifth and last planned divestiture since it announced its intent in July to market non-core businesses with combined revenues of $500 million. A&I has been part of Lubrizol's consumer specialties product line in the Specialty Chemicals segment. A&I management anticipates that 2006 sales revenues will be approximately $30 million U.S. Terms of the sale were not disclosed. A&I develops and produces active pharmaceutical ingredients and advanced intermediates that are marketed to proprietary and generic drug manufacturers worldwide.
Topics
Organizations
Other news from the department business & finance
These products might interest you
AZURA Purifier + LH 2.1 by KNAUER
Preparative Liquid Chromatography - New platform for more throughput
Save time and improve reproducibility during purification
Pharmaceutical Substances by Thieme Verlag
Look up Industrial Syntheses of 2,600 APIs
Your tool for Syntheses, Patents and Applications – Pharmaceutical Substances
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.